Boehringer's sales slide triggers job-chopping in Connecticut

Boehringer Ingelheim's global restructuring--prompted by the German pharma's sales struggle--is now manifesting itself in Connecticut, where the company is laying off staffers in Ridgefield. As a BI spokesperson told FierceBiotech, the move affects less than 5% of its 2,700-strong workforce there, but the company is looking to find new positions for some of the people involved in the cutback. "Boehringer Ingelheim is in the process of rebalancing its workforce in the U.S. to put the company in the best position for future growth," it said in a statement. Report

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.